Compare Best Buy Co Inc (BBY) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Best Buy Co Inc vs Novo Nordisk A/S — how do they compare? Best Buy Co Inc trades at $83.24 (market cap $17.55B), while Novo Nordisk A/S trades at $46.25 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 11.8× Best Buy Co Inc's market cap, and Best Buy Co Inc pays the higher dividend (4.61%). Which is the better fit depends on your goals.
| BBY | NVO | |
|---|---|---|
Market Cap | $17.55B | $207.85B |
Sector | Consumer Cyclical | Health |
52-Week High | $90.17 | $63.98 |
52-Week Low | $55.52 | $35.29 |
Enterprise Value | $19.93B | $222.55B |
Dividend Yield | 4.61% | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BBY trades at $83.24, up 0.98% on the day, near the consensus price target of $84.31. The stock shows a neutral technical signal with bullish moving averages. Recent earnings have consistently beaten estimates, and the company maintains solid profitability with a 39.1% ROE. Leadership changes, including a new CFO, and store format tests aim to drive future growth amid declining revenues.
The outlook is mixed: strong cash flow improvement and shareholder returns via dividends support upside, but revenue declines and competitive pressures pose risks. Analysts are cautious with a 'Hold' majority. Investors should weigh valuation attractiveness against execution challenges in a tough retail environment.
NVO trades at $47.73, up 0.99% today, with a neutral technical signal and strong fundamentals, including a P/E of 11.62 and net income margin of 35.35%. Recent Q2 2026 earnings beat expectations, but the stock faces mixed sentiment due to competitive pressures and pricing headwinds in its GLP-1 portfolio.
The outlook is cautiously optimistic, supported by robust profitability and analyst buy ratings (57.9%), but risks include intense competition from Eli Lilly and margin compression. Upside potential hinges on execution against guidance, while downside risks stem from market share erosion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Best Buy Co Inc
With $51.8 billion in fiscal 2022 sales, Best Buy is the largest pure-play consumer electronics retailer in the U.S., with roughly 10.6% share of the aggregate market and north of 40% share of offline sales, per our calculations, CTA industry, and Euromonitor data. The firm generates the bulk of its sales in-store, with mobile phones and tablets, computers, and appliances representing its three largest categories. Recent investments in e-commerce fulfillment, accelerated by the COVID-19 pandemic, have seen the U.S. e-commerce channel roughly double from prepandemic levels, with management estimating that it will represent a mid-30% proportion of sales moving forward.
Read more on BBY →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
